Ovarian Cancer


Author: Ning Wen Background: The Forkhead box M1 (FOXM1), an important regulator of cell differentiation and proliferation, is overexpressed in a number of aggressive human carcinomas. The purpose of this study was to examine the expression levels of FOXM1 in epithelial ovarian cancer (EOC), to identify the relationship between FOXM1 […]

Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell ...


Author: Je-Gun Joung Background: Clinical statement alone is not enough to predict the progression of disease. Instead, the gene expression profiles have been widely used to forecast clinical outcomes. Many genes related to survival have been identified, and recently miRNA expression signatures predicting patient survival have been also investigated for […]

Integrated analysis of microRNA-target interactions with clinical outcomes for cancers



Author: Isabelle Matte Background: Malignant ascites is often present at diagnostic in women with advanced ovarian cancer (OC) and its presence is associated with a worse outcome. Human peritoneal mesothelial cells (HPMCs) are key components of malignant ascites. Although the interplay between HPMCs and OC cells is believed to be […]

Role of malignant ascites on human mesothelial cells and their ...


Author: Hyo Sook Bae Background: Studies on the association between obesity and ovarian cancer survival have had conflicting results. We reviewed and quantitatively summarized the existing evidence, exploring potentially important sources of variability, such as the timing of body mass index (BMI) assessment, BMI cut points, references used in multivariate […]

Obesity and epithelial ovarian cancer survival: a systematic review and ...



Author: Zhiqiang Guo Background: T-cell immunoglobulin and mucin domain 3 (TIM-3) is known as a negative immune regulator and emerging data have implicated TIM-3 a pivotal role in suppressing antitumor immunity. The co-stimulatory receptor CD137 is transiently upregulated on T-cells following activation and increases their proliferation and survival when engaged. […]

Combined TIM-3 blockade and CD137 activation affords the long-term protection ...


Author: Anna Bachmayr-Heyda Background: Epithelial ovarian cancer is one of the most lethal gynecologic malignancies. Clinicopathological factors do not permit precise prognosis and cannot provide guidance to specific treatments. In this study we assessed tumor infiltrating CD8+ T cells in association with Ki67 proliferation index and evaluated their prognostic impact […]

Prognostic impact of tumor infiltrating CD8+ T cells in association ...



Author: Patrizia Vici Background: Currently, no clearly superior management strategy exists for recurrent, platinum-resistant ovarian cancer. We tested the efficacy and safety of gemcitabine combined with oxaliplatin (GEMOX) in a multicentre phase II clinical trial. Methods: Forty one patients with recurrent, platinum-resistant ovarian cancer were enrolled. Prior to study entry, […]

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer ...


Author: Deok-Soo Son Background: Ovarian cancer, an inflammation-associated cancer, is the fifth leading cause of cancer deaths in women. The malignancy produces a large amount of tumor necrosis factor (TNF) which promotes a proinflammatory tumor microenvironment. In addition, the epidermal growth factor receptor (EGFR) is frequently overexpressed in high-grade ovarian […]

Characteristics of chemokine signatures elicited by EGF and TNF in ...



Author: Yakup Kumtepe Background: Human HIV-1 TAT interactive protein 2 (HTATIP2/TIP30) is an evolutionarily conserved gene that is expressed ubiquitously in human tissues and some tumor tissues. This protein has been found to be associated with some gynecological cancers; as such, this study aimed to investigate blood HTATIP2/TIP30 levels in […]

High serum HTATIP2/TIP30 level in serous ovarian cancer as prognosti ...


Author: Jian Gao ObjectiveThis study investigates the expression of Lewis y antigen, integrin alphav, beta3 in epithelial ovarian cancer tissues. We further evaluate the relationship between their expression and chemotherapy resistance of ovarian cancer and its possible clinical significance. Methods: Tissues of 92 patients with ovarian cancer meeting the inclusion […]

Expression of Lewis y antigen and integrin alphav, beta3 in ...



Author: Matthew J Schultz Background: Platinum drugs, including cisplatin, are a frontline therapeutic in ovarian cancer treatment and acquired resistance to these agents is a major contributor to ovarian cancer morbidity and mortality. In this study a novel glycosylation-dependent mechanism for cisplatin resistance is described. Specifically, cisplatin-induced cell death is […]

ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells


Author: Dietmar Pils Background: The immune system is a key player in fighting cancer. Thus, we sought to identify a molecular ‘immune response signature’ indicating the presence of epithelial ovarian cancer (EOC) and to combine this with a serum protein biomarker panel to increase the specificity and sensitivity for earlier […]

A combined blood based gene expression and plasma protein abundance ...



Author: Marjolein Kleppe Background: The concept of sentinel lymph node surgery is to determine whether the cancer has spread to the very first lymph node or sentinel node. If the sentinel node does not contain cancer, then there is a high likelihood that the cancer has not spread to other […]

Sentinel node in ovarian cancer: study protocol for a phase ...


Author: Sabine Heublein Background: Anti-Her-2 treatment is successfully administered to Her-2 overexpressing breast cancer patients and significantly implicates upon their survival. Building on these promising results, anti-Her-2 treatment protocols were tested as an option for epithelial ovarian cancer (EOC) as well. However Her-2 signalling is known to be modulated by […]

Her-2/neu expression is a negative prognosticator in ovarian cancer cases ...